
News|Videos|June 4, 2015
Mismatch Repair-Deficient Colorectal Tumors Responded to Pembrolizumab
Author(s)Dung T. Le, MD
In this video, Dung T. Le, MD, discusses a phase II study that found that mismatch repair–deficient colorectal tumors were highly responsive to checkpoint blockade with the anti–PD-1 drug pembrolizumab.
Advertisement
In this video, Dr. Le discusses a phase II study that found that colorectal tumors lacking the ability to repair DNA-or mismatch repair–deficient tumors-were highly responsive to checkpoint blockade with the anti–programmed death 1 (PD-1) drug pembrolizumab. The data were presented at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting.
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Advertisement
Advertisement
Advertisement
Trending on CancerNetwork
1
In Vivo CAR Engineering and the Next Phase of Cellular Immunotherapy
2
3 Things You Should Know About TROP2-Directed Antibody-Drug Conjugates in the Frontline Treatment of Metastatic Triple-Negative Breast Cancer
3
Synchronous Endometrial and Ovarian Cancers: A Case Study and Literature Review
4
This Week in Oncology: Real-World NSCLC Care and AACR 2026 Updates
5
























































